Wave Life Sciences USA, Inc.

Clinical trials sponsored by Wave Life Sciences USA, Inc., explained in plain language.

Wave Life Sciences USA, Inc. WVE NASDAQ

A biotech company developing RNA-based therapies for genetic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

RNA editing drug hopes to fix genetic flaw in rare lung and liver disease Results expected Sep 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 2 Completed 1 Terminated 1

Spinal injection drug targets genetic cause of ALS and dementia

Disease control Stopped early

Researchers are testing repeated doses of an experimental drug called WVE-004 in adults who have ALS, frontotemporal dementia, or both, linked to a mutation in the C9orf72 gene. Participants receive the drug by spinal injection every 12 weeks for up to 96 weeks. The study tracks …

Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control

Last updated Sep 11, 2026 00:00 UTC

Wave Life Sciences USA, Inc.

Upcoming readouts

Spinal injection drug targets genetic cause of ALS and dementia